Shilpa Medicare Limited

SHILPAMED

INE790G01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:52 2024-06-28 am EDT			5-day change	1st Jan Change
569.6 ^INR	+1.61%		-1.68%	+72.38%

Jun. 25	Shilpa Medicare Bio Analytical Unit Gets "No Action Indicated" Classification from US FDA	MT
May. 24	Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024

Shilpa Medicare Limited Announces Resignation of Ajeet Singh Karan as Independent Director

April 15, 2019 at 06:35 am EDT

Shilpa Medicare Limited announced that Mr. Ajeet Singh Karan an Independent Director of the Board of the Company, has submitted his resignation which has been accepted with effect from 15th April, 2019 due to his preoccupation that is he is starting his own venture.

Latest news about Shilpa Medicare Limited

Shilpa Medicare Bio Analytical Unit Gets "No Action Indicated" Classification from US FDA	Jun. 25	MT
Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024	May. 24
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 23	CI
Shilpa Medicare Limited Announces Successful Completion of Early Clinical Development and Ongoing Phase 3 Clinical Trial of Its Newly Developed Drug "SML-007", for the Treatment of Non-Alalcoholic Fatty Liver Disease	May. 14	CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	Apr. 18	MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	Apr. 17	MT
Shilpa Medicare Gets Board Nod to Launch QIP	Apr. 09	MT
Shilpa Medicare's Life Science Arm Names CEO	Mar. 28	MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA	Mar. 01	MT
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe	Feb. 26	MT
Transcript : Shilpa Medicare Limited, Q3 2024 Earnings Call, Feb 12, 2024	Feb. 12
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug	Jan. 19	MT
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Shilpa Medicare Acquires US-Based Pilnova Pharma	Nov. 02	MT
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal	23-10-11	CI
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection	23-09-04	MT
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms	23-09-04	MT
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg	23-09-01	CI
Shilpa Medicare's Manufacturing Facility in Telangana Gets Clearance from Brazilian Regulator	23-08-25	MT
Transcript : Shilpa Medicare Limited, Q1 2024 Earnings Call, Aug 11, 2023	23-08-11
Shilpa Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Shilpa Medicare Limited Announces Issuance of Redeemable Non-Convertible Debentures for its 2 Wholly Owned Subsidiaries	23-08-08	CI
Shilpa Medicare Gets Regulatory Nod for Pemetrexed Injections	23-07-31	MT
Shilpa Medicare Limited Receives Approval from CDSCO, New Delhi for Manufacturing and Sale of Lenvatinib Capsules, 12, 18 and 24 mg in India	23-06-29	CI

Chart Shilpa Medicare Limited

Duration

Period

More charts

Company Profile

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHILPA MEDICARE LIMITED	+72.38%	593M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals